-+ 0.00%
-+ 0.00%
-+ 0.00%

Matisse Pharmaceuticals raises €14 million in Series A led by investors including Brightlands Venture Partners

PUBT·09/17/2026 21:22:27
Listen to the news
Matisse Pharmaceuticals raises €14 million in Series A led by investors including Brightlands Venture Partners
  • Matisse Pharmaceuticals raised EUR 14 million in a Series A round to fund Phase 2 development of its sepsis drug candidate.
  • Brightlands Venture Partners BV participated alongside LIOF, private investors, and management in the company-led financing.
  • Proceeds target a Phase 2 clinical trial of isupartob sodium, with additional funding for regulatory, manufacturing, and operations.
  • Matisse is a clinical-stage developer of isupartob sodium, positioned as a differentiated approach for treating sepsis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightlands Venture Partners BV published the original content used to generate this news brief on September 17, 2026, and is solely responsible for the information contained therein.